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IMPORTANCE Antiretroviral therapy (ART) is the cornerstone of prevention andmanagement
of HIV infection.
OBJECTIVE To evaluate new data and treatments and incorporate this information into
updated recommendations for initiating therapy, monitoring individuals starting therapy,
changing regimens, and preventing HIV infection for individuals at risk.
EVIDENCE REVIEW New evidence collected since the International Antiviral Society–USA 2016
recommendations via monthly PubMed and EMBASE literature searches up to April 2018;
data presented at peer-reviewed scientific conferences. A volunteer panel of experts in HIV
research and patient care considered these data and updated previous recommendations.
FINDINGS ART is recommended for virtually all HIV-infected individuals, as soon as possible
after HIV diagnosis. Immediate initiation (eg, rapid start), if clinically appropriate, requires
adequate staffing, specialized services, and careful selection of medical therapy.
An integrase strand transfer inhibitor (InSTI) plus 2 nucleoside reverse transcriptase
inhibitors (NRTIs) is generally recommended for initial therapy, with unique patient
circumstances (eg, concomitant diseases and conditions, potential for pregnancy, cost)
guiding the treatment choice. CD4 cell count, HIV RNA level, genotype, and other laboratory
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during ART. If a regimen switch is indicated, treatment history, tolerability, adherence,
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sexually active andmore often for individuals at ongoing risk for infection. Preexposure
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N ewdrugsandnewapproachestopreventandmanageHIVinfection necessitate an update to the International An-tiviral (formerlyAIDS)Society–USA(IAS-USA) recommen-
dations, lastpublished in2016.1This report incorporatescurrentdata
on new regimens and new approaches into recommendations for
the treatment and prevention of HIV.
Methods
Recommendationswere developed by an international panel of 16
volunteerexperts inHIV researchandcare.Memberswerescreened
for expertise, involvement in research and care, financial relation-
ships, and ability to work toward consensus (ie, ability to consider
all available data, evidence, and group discussions or opinions to
reachagreementonrecommendations).Thepanel convened inper-
son (N =2) and by conference calls (N = 10 full-panel and multiple
subgroupcalls) fromSeptember2017 to June2018. Teams for each
section evaluated relevant evidence and drafted recommenda-
tions for full-panel review.
New evidence usedwas published in the literature, presented
atmajor conferences, or releasedas safety reports.1Monthly litera-
ture searches were conducted in PubMed and EMBASE between
July2016andApril 2018.Approximately237 relevant citationswere
identified frommore than4490reports.Abstractspresentedat sci-
entific conferences since July 2016were identified. Relevant scien-
tific publications or abstracts presented at peer-reviewed confer-
ences were requested from drugmanufacturers.
These updated recommendations focus on adults (18 years)
with or at risk for HIV infection in settings in whichmost antiretro-
viral drugs are available or in late-stagedevelopment (newdrugap-
plication filed). Recommendations were made by consensus and
rated according to strength of the recommendation and quality of
theevidence (Table 1). For recommendations thathavenotchanged
substantiallyor forwhich fewnewdatahavebecomeavailable since
2016, the prior report should be reviewed.1 Details about the de-
velopment process, panel, evidence collection and literature
searches, and sponsor (IAS-USA) and its policies are reported in the
Supplement.
When to Start
Recommendations for initiatingantiretroviral therapy(ART)aresum-
marized inBox 1. InpatientswithestablishedHIV,ARTshouldbe ini-
tiated as soon as possible after diagnosis.1 The question ofwhen to
start ART is focused now onwhether immediate ART (same day to
14 days after diagnosis) is preferred. The World Health Organiza-
tionendorsedART initiationwithin 7daysof newdiagnosis (includ-
ing same day), citing improved viral suppression.4 Rapid initiation
of ART requires improving linkage to care and addressing struc-
tural barriers (eg, staffingandservices availability)within clinics and
ART distribution systems.
Rapid ART Start
Randomized trials in Lesotho, Haiti, and South Africa showed sig-
nificant improvements in viral load suppression at 10 or 12months
and retention in care with rapid initiation of therapy.5-7 In 1 study,
individuals were randomized to early ART with simplified counsel-
ing and point-of-care CD4 cell assays or to standard care. In the in-
tervention group, 80% began ARTwithin 14 days and 71% started
ART the same day of eligibility, compared with 38% and 18%, re-
spectively, in the control group. Virologic suppression at 1 yearwas
improved in the intervention group (85% vs 75%).8
Several cohorts examined the feasibility, outcomes, and chal-
lenges of rapid ART start.9 Meta-analyses of 8 cohorts showed an
improvement in the proportion of patients starting ART within 3
months but no benefit on retention in care.10 A statistically non-
significant trend toward worse viral suppression was observed for
those who started ART rapidly in 1 cohort.10 San Francisco imple-
mented a citywide rapid ART program in which newly diagnosed
persons were linked to care within 5 days from diagnosis and
offered treatment on the day of their clinic visit. Of 265 newly
diagnosed persons, 97% were linked to care (30% within 5 days)
and 81% started ART; time from diagnosis to HIV RNA level below
200 copies/mL decreased by more than 50% and time from first
care visit to ART decreased from 27 days to 1 day.11,12 A large HIV
clinic in Atlanta implemented rapid access to ART on the day of
the initial visit. Median time from initial diagnosis to HIV-1 RNA
level below 200 copies/mL decreased from 67 to 41 days; how-
ever, the program was not sustainable because of increased
patient load and inadequate funding for staffing.13
Despitethesuccessof rapidARTinitiation insomesettings, start-
ingARTon thedayofdiagnosis requires coordinationbetween test-
ing and treatment settings and access to resources that may limit
treatment uptake. All elements of conventional treatment initia-
tionmustbe inplaceat the treatment sitebutprovided inaway that
ensures immediate access.12
ART initiation, including rapid start, is recommended for all
infected ambulatory patients committed to starting ART (unless
the patient has symptoms that suggest an opportunistic infection
for which immediate ART is contraindicated) or for those with
unclear HIV diagnosis (eg, discordant serologic or rapid test
results) (evidence rating AIII). Because of concerns about trans-
mitted drug resistance (eg, K103N mutation), immediate ART
should not be nonnucleoside reverse transcriptase inhibitor
(NNRTI)–based (evidence rating AIII). Dolutegravir/tenofovir
alafenamide (TAF) (or tenofovir disoproxil fumarate [TDF])/
emtricitabine (or lamivudine) or bictegravir/TAF/emtricitabine or
boosted darunavir TAF (or TDF)/emtricitabine (or lamivudine) are
recommended for rapid initiation (AIII). Patients requiring aba-
cavir should not begin until the result of testing for the HLA-
B*5701 allele is available (evidence rating AIa).
When to Start ART in the Setting of Active
Opportunistic Infections andMalignancies
Recommendations for initiating ART in the setting of active oppor-
tunistic infections (OIs) remain unchanged.1 ART should be started
within the first 2 weeks after diagnosis for most OIs (evidence rat-
ing AIa). Data further support the recommendation to start ART
within the first 2weeksof initiationof tuberculosis treatment forpa-
tients with CD4 cell counts below 50/μL and within the first 2 to 8
weeks for those with CD4 cell counts of 50/μL and above (evi-
dence ratingAIa). Forpatientswith cryptococcalmeningitis inhigh-
resourced settings with access to optimal antifungal therapy, fre-
quent monitoring, and aggressive management of intracranial
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pressure, ART should begin within 2 weeks of diagnosis.14,15 Care-
ful monitoring for immune reconstitution inflammatory syndrome
isessential.For individualsdiagnosedwithHIVandamalignancycon-
currently, ART should be initiated immediately.3 Early adverse ef-
fects of ART can be monitored and managed while cancer staging
andmolecular testing are performed.
Primary OI Prophylaxis
With ART universally recommended, the incidence of Pneumocys-
tis pneumonia and major AIDS-associated OIs has declined to less
than 1.45 and0.4 per 100 person-years, respectively, in the United
States.16 For individualswithviral suppressionwhile takingART, the
incidenceandoverallmortalityofMycobacteriumaviumcomplexdis-
ease is sufficiently low17,18 that primaryMycobacteriumavium com-
plex prophylaxis is no longer recommended (evidence rating AIIa).
Primary prophylaxis for Pneumocystis pneumonia is still recom-
mended forpatientsmeetingCD4criteria (evidence ratingAIa).17,19
Primary prophylaxis for cryptococcal disease is not recommended
in settings where incidence is low (evidence rating AIII).
Recommended Initial Regimens
Recommendations for initial ART are summarized in Box 2. Regi-
mens thatdonot requireboostingwith ritonavir or cobicistat are fa-
vored. Choosing a combination with a high barrier to resistance is
important, particularly for individuals with inconsistent adher-
ence.AsmoregenericARTmedicationsbecomeavailable, cost and
access tomedications are likely tobeof increasing importance (see
below). Regimens are also listed for patients who cannot take the
generally recommended initial regimensowing toanticipatedprob-
lems with adherence, drug interactions, patient preference, finan-
cial considerations, or lack of availability of recommended options.
Recommended initial ART for most patients is listed in alpha-
betic order by integrase strand transfer inhibitor (InSTI) compo-
nent (see also Table 2 for medications and their associated advan-
tagesanddisadvantages).Bictegraviranddolutegravirdonot require
pharmacologic boosting, have a high barrier to resistance, and are
part of regimenswith a lowpill burdenand toxicity. Studiesof these
drugs in initial regimens have shown comparable efficacy and no
emergenceof resistant virus.20,21 There are substantiallymoredata
and longer-term experience with dolutegravir (approved in the
UnitedStates in2013) thanwithbictegravir (approved in2018).Pre-
liminarydatahaveraisedconcerns regardinguseofdolutegravir (and
potentially other InSTIs) for individuals capable of becoming preg-
nant (see below). Raltegravir is well tolerated and has fewer drug
interactions than other InSTIs but has a lower barrier to resistance
andahigherpill burden.Elvitegravir regimensalsohavea lowerbar-
rier to resistance and include a pharmacologic booster (cobicistat)
that results in more drug interactions.
In combination with 2 nucleoside reverse transcriptase inhibi-
tors (NRTIs), the NNRTIs efavirenz and rilpivirine each demon-
stratehigh ratesofvirologic suppressionas initial therapy.Efavirenz-
based treatment was standard initial therapy for many years, but
studieshavedemonstratedhigher ratesof adverseeffects (rashand
central nervous system adverse effects) than InSTI-based therapy.
Rilpivirine has a lower rate of central nervous system adverse ef-
fects and rash than efavirenz and is coformulated with TAF/
emtricitabine into the smallest single tablet for initial therapy.How-
ever, rilpivirine must be taken with food, requires stomach acidity
Table 1. Strength of Recommendation andQuality of Evidence
Rating Scalea
Category, Rating Definition
Strength of Recommendation
A Strong support for the recommendation
B Moderate support for the recommendation
C Limited support for the recommendation
Quality of Evidence
Ia Evidence from ≥1 randomized clinical trials published
in the peer-reviewed literature
Ib Evidence from ≥1 randomized clinical trials presented
in abstract form at peer-reviewed scientific meetings
IIa Evidence from nonrandomized clinical trials or cohort
or case-control studies published in the peer-reviewed
literature
IIb Evidence from nonrandomized clinical trials or cohort
or case-control studies presented in abstract form
at peer-reviewed scientific meetings
III Recommendation based on the panel’s analysis
of the accumulated available evidence
a Adapted in part from Canadian Task Force on Periodic Health Examination.2
Box 1. Selected Recommendations forWhen to Start ART
ART should be initiated as soon as possible after diagnosis,
including immediately after diagnosis, unless patient is not ready
to commit to starting therapy (evidence rating AIa).
Structural barriers that delay receipt of ART should be removed to
allow newly diagnosed persons to receive ART at the first clinic
visit after diagnosis, if they and their clinician determine that this
approach is appropriate (evidence rating AIa).
Samples for HIV-1 RNA level; CD4 cell count; HIV genotype for
NRTI, NNRTI, and PI; laboratory tests to exclude active viral
hepatitis; and chemistries should be drawn before beginning ART,
but treatment may be started before results are available. Result
of testing for HLA-B*5701 allele should be available if an
abacavir-containing regimen is anticipated (evidence rating AIa).
NNRTIs and abacavir should not be used for rapid ART start
(evidence rating AIII).
ART should be started as soon as possible but within the first 2
weeks after diagnosis for most OIs (evidence rating AIa).
Primary MAC prophylaxis is no longer recommended if effective
ART is initiated (evidence rating AIIa).
Primary prophylaxis for Pneumocystis pneumonia should be
initiated for patients with CD4 cell counts below 200/μL
(evidence rating AIa).
Prophylaxis for cryptococcal disease is not recommended
in highly resourced settings with low prevalence of disease
(evidence rating AIII).
ART should be implemented immediately in the setting of newly
diagnosedmalignancy, with attention to drug-drug interactions
(evidence rating BIIa).3
Abbreviations: ART, antiretroviral therapy; MAC,Mycobacterium avium
complex; NNRTI, nonnucleoside reverse transcriptase inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; OI, opportunistic infection;
PI, protease inhibitor.
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foradequateabsorption, and is recommendedonly forpatientswith
baselineHIVRNAlevelbelow100000copies/mLandCD4cell count
above 200/μL.
TheNNRTI doravirine is currently under investigation for initial
therapy. Inphase3 trials, doravirinewasnoninferior toefavirenzand
toritonavir-boosteddarunavir inachievingvirologicsuppressionand
hadfewercentralnervoussystemadverseevents thanefavirenzand
a better lipid profile than either efavirenz or ritonavir-boosted
darunavir.22,23Thus,doravirinemaybepreferabletoexistingNNRTIs,
but no prospective studies compare it with InSTI-based regimens.
Non-InSTI initial regimens are summarized in Table 3.
Abacavir is a componentof the recommended regimendolute-
gravir/abacavir/lamivudine. Individualswhotestpositive for theHLA-
B*5701 allele are at risk of a potentially life-threatening hypersen-
sitivity reaction to abacavir.1 Results ofHLA-B*5701 testingmustbe
available before use (evidence rating AIa); patients who test posi-
tive should not be given abacavir (evidence rating AIa), and this in-
formation should be documented in themedical record.
Although some prior comparisons of abacavir/lamivudine and
TDF/emtricitabine demonstrated an efficacy advantage of TDF/
emtricitabine in patients with high HIV-1 RNA levels,1 the differ-
ences have not been observed in studies that use InSTIs.20 Aba-
cavir has no activity against hepatitis B virus (HBV) and should not
be used in patients with HIV and HBV.
TAF-andTDF-containingregimensaresimilarvirologically.Com-
paredwith TDF, TAF results in a lower plasma level of tenofovir and
higher intracellular concentration of the active antiviral compo-
nent tenofovir diphosphate. This results in fewer tenofovir-
associated renal and bone toxic effects.25 These differences be-
tweenTAFandTDFareaccentuatedwhenTDF isusedwith ritonavir
or cobicistat, which increase tenofovir plasma levels.26
Two-Drug Initial Therapy
Initial 2-drug regimensareunder investigation.This strategymayof-
fer cost or toxicity advantages over standard 3-drug regimens, but
efficacyneeds tobe confirmed.27Darunavir/ritonavir plus raltegra-
virwasnoninferior todarunavir/ritonavirplus2NRTIs,but the2-drug
regimenhadhigher ratesof treatment failure inpatientswith aCD4
cell count below 200/μL or an HIV RNA level above 100 000
copies/mL.28
Dolutegravir plus lamivudine and darunavir/ritonavir plus
lamivudine are being studied.29,30 Until further data are avail-
able, initial 2-drug regimens are reserved for the rare situation
when individuals cannot take abacavir, TAF, or TDF. In this situa-
tion, darunavir/ritonavir plus raltegravir (if <100 000 HIV RNA
copies/mL and CD4 cell count >200/μL) or darunavir/ritonavir plus
lamivudine may be used (if there is no lamivudine resistance) (evi-
dence rating BIa). Short-term data from comparative trials may
provide support for dolutegravir plus lamivudine as initial 2-drug
therapy(NCT02831764).Dolutegravirplusrilpivirinehasnotyetbeen
assessed for initial therapy.31
Unique Considerations
Pregnancy
Individuals who are pregnant should initiate ART as soon as
possible for their own health and to reduce transmission to the
infant (evidence rating AIa).1 The NRTI options include abacavir/
lamivudine (or emtricitabine) if patient tests negative for HLA-
B*5701orTDF/emtricitabine (or lamivudine). Insufficient safetydata
for TAF preclude use of this drug during pregnancy.
A preliminary report revealed neural tube defects among in-
fants born to women taking a dolutegravir-containing regimen at
conception, suggesting, fornow, thatdolutegravir shouldbeavoided
in individualsof childbearingagewhowish tobecomepregnant, are
trying to get pregnant, or are sexually active and not reliably using
Box 2. Selected Recommendations for Initial ART Regimensa
Generally Recommended Initial Regimens (Listed in Alphabetic
Order by InSTI Component)
• Bictegravir/TAF/emtricitabine (evidence rating AIa)b
• Dolutegravir/abacavir/lamivudine (evidence rating AIa)c,d
• Dolutegravir plus TAF/emtricitabine (evidence rating AIa)c,e
Recommended Initial Regimens for Individuals forWhomGenerally
RecommendedRegimens AreNot Available or Not anOption
(Listed in Alphabetic Order by First Component)
• Darunavir/cobicistat plus TAF (or TDF)/emtricitabine
(evidence rating AIa)e
• Darunavir boosted with ritonavir plus TAF (or TDF)/emtricitabine
(evidence rating AIa)e
• Efavirenz/TDF/emtricitabine (evidence rating AIa)
• Elvitegravir/cobicistat/TAF (or TDF)/emtricitabine
(evidence rating AIa)e
• Raltegravir plus TAF (or TDF)/emtricitabine
(evidence rating AIa for TDF)e
• Rilpivirine/TAF (or TDF)/emtricitabine (if pretreatment HIV RNA
level is <100000 copies/mL and CD4 cell count is >200/μL)
(evidence rating AIa)e
TDF is not recommended for individuals with or at risk for
kidney or bone disease (osteopenia or osteoporosis)
(evidence rating BIII).
Initial 2-drug regimens are only recommended in the rare
situations in which a patient cannot take abacavir, TAF, or TDF
(evidence rating BIa).
Pregnant individuals with HIV infection should initiate ART for
their own health and to reduce the likelihood of HIV transmission
to the infant (evidence rating AIa).
Abbreviations: ART, antiretroviral therapy; InSTI, integrase strand transfer
inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
a Components separated with a slash (/) indicate that they are available
as coformulations.
b There are fewer long-term safety and efficacy data with bictegravir than
with dolutegravir.
c There are important considerations related to interim reports of potential
teratogenicity of dolutegravir when initiated before conception. See text
for details.
d Testing for HLA-B*5701 allele should be performed before abacavir use
(evidence rating AIa); patients who test positive should not be given
abacavir (evidence rating AIa). Because it typically takes several days or
longer to obtain results for HLA-B*5701 testing, tenofovir-containing
regimens should be used when starting ART on the same day as HIV
diagnosis or until HLA-B*5701 testing results are available. In patients with
or at high risk for cardiovascular disease, a tenofovir-containing regimen,
rather than an abacavir-containing regimen, should be used if possible.
e In settings in which TAF/emtricitabine is not available or if there is a
substantial cost difference, TDF (with emtricitabine or lamivudine) is
effective and generally well tolerated, particularly if the patient does not
have, or is not at high risk for, kidney or bone disease.
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contraception.32All individualsofchildbearingageshouldhavedocu-
mentationofanegativepregnancytest resultbeforestartingdolute-
gravir and should be counseled regarding this potential risk. More
dataareexpected; it isnotyetclearwhetherother InSTIsposeasimi-
lar risk of neural tube defects.
Raltegravir is the recommended InSTI for individuals who are
alreadypregnant. Elvitegravir/cobicistat should not beusedduring
pregnancy (evidence rating AIIa). Pregnant women already taking
elvitegravir/cobicistat should be switched to a recommended
regimen.33 Bictegravir should not be used during pregnancy be-
cause available safety data are insufficient.
Recommended protease inhibitors (PIs) include atazanavir/
ritonavir (once daily) or darunavir/ritonavir (twice daily). Drugs
boosted with cobicistat (eg, darunavir/cobicistat and atazanavir/
cobicistat) are not recommended for use during pregnancy be-
causeofpharmacokineticconcernsor insufficientdata (evidencerat-
ing AIIb).32 Efavirenz and rilpivirine are alternatives in pregnancy.
Therewere initial concerns regarding potential neural tube defects
withefavirenz,but accumulateddatanowsupport the safetyofefa-
virenz during pregnancy.
HBV andHepatitis C Virus Co-infection
HIV-infected patients with HBV co-infection should initiate an ART
regimen that contains TDF or TAF (evidence rating AIa), lamivu-
dineoremtricitabine, anda thirdcomponent.34-36PatientswithHIV
co-infectedwithhepatitisCvirus (HCV)arecandidates forHCVtreat-
mentandthereforeshouldstartanARTregimenwithdrugsthathave
minimaldrug interactionswithHCVtherapies (evidence ratingAIIa),
such as dolutegravir/abacavir/lamivudine, dolutegravir/TAF/
emtricitabine,bictegravir/TAF/emtricitabine,or raltegravirplusTAF/
emtricitabine.CliniciansshouldconsultcurrentHCVtreatmentguide-
lines (https://www.hcvguidelines.org).
Bone, Kidney, and Cardiovascular Disease
HIV is associated with osteoporosis and fractures.37 Baseline bone
mineraldensity testing is recommended inpostmenopausalwomen
and in anyone older than 50 years (evidence rating BIII). During
the first 1 to 2 years after ART initiation, patients may lose 2% to
6% of bone mineral density at the hip and spine. Patients taking
TDF-containing regimenshave a greater initial decline in bonemin-
eral density than those who take a TAF- or abacavir-containing
regimen.1,20,38 Accordingly, TDF is not recommended for patients
withosteopeniaorosteoporosis (evidenceratingBIII).Abacavirdoes
not require dose adjustment based on renal function. TAF can be
used if creatinine clearance is above 30mL/min/1.73 m2 (evidence
ratingAIIa).1 Dose reduction of lamivudine is recommended for pa-
tientswithcreatinineclearancebelow50mL/min/1.73m2.Thereare
datasupportinguseofelvitegravir/cobicistat/TAF/emtricitabineonce
daily in patients with end-stage renal disease (estimated glomeru-
lar filtration rate <15 mL/min) receiving long-term hemodialysis.39
HIV-infectedpatientswithend-stage renal disease shouldbeevalu-
ated for kidney transplantation (evidence rating AIIa).
Table 2. Advantages and Disadvantages of Currently Available Integrase Strand Transfer Inhibitors
Druga
Year of FDA
Approval Advantages Disadvantages
Bictegravir 2018 Coformulated with TAF/emtricitabine as part of a
complete initial regimen
Noninferior to dolutegravir in comparative trials
Once-daily dosing
Low risk of resistance with virologic failure
Relatively few drug interactions
Can be taken with or without food
Can be started without HLA-B*5701 testing
Coformulation precludes combination with other antiretrovirals
Cannot be used with rifampin
Less long-term experience and data than with other InSTIs
Raises serum creatinine levels (≈0.1 mg/dL) through inhibition of
tubular secretion of creatinine
Insufficient data in pregnant women
Concerns regarding neural tube defects in infants born to women who
conceived while taking dolutegravir; unknown whether this is a class
effect (see text)
Dolutegravir 2013 Noninferior to bictegravir in 2 comparative trials and
superior to darunavir and efavirenz in comparative trials
Once-daily dosing
Available as a single agent, allowing it to be used in other
combinations
Low risk of resistance with virologic failure
Relatively few drug interactions
Can be taken with or without food
Superior to raltegravir in treatment-experienced patients
Raises serum creatinine levels (0.1–0.15 mg/dL) through inhibition of
tubular secretion of creatinine
Higher rates of insomnia and headache than with comparators in some
studies
Coformulated with abacavir/lamivudine, is the largest tablet among
coformulated single-pill regimens; abacavir requires HLA-B*5701
testing
Concerns regarding neural tube defects in infants born to women who
conceived while taking dolutegravir; unknown whether this is a class
effect (see text)
Elvitegravir 2012 Once-daily dosing
Coformulated with TDF/emtricitabine or
TAF/emtricitabine as a complete regimen
Requires pharmacokinetic boosting with cobicistat for once-daily dosing
Lower barrier to resistance than bictegravir and dolutegravir
Frequent drug interactions attributable to cobicistat boosting
Cobicistat raises serum creatinine levels (0.1-0.15 mg/dL) through
inhibition of tubular secretion of creatinine
Should be taken with food
Should be avoided in pregnant women because of inadequate plasma
levels
Concerns regarding neural tube defects in infants born to women who
conceived while taking dolutegravir; unknown whether this is a class
effect (see text)
Raltegravir 2007 Superior to ritonavir-boosted atazanavir and
ritonavir-boosted darunavir in a comparative clinical trial
Longest safety record
Fewest drug interactions
Can be taken with or without food
Not coformulated as part of a complete regimen
Lower barrier to resistance than bictegravir or dolutegravir
Higher pill burden than with other InSTIs
Concerns regarding neural tube defects in infants born to women who
conceived while taking dolutegravir; unknown whether this is a class
effect (see text)
Abbreviations: FDA, US Food and Drug Administration; InSTI, integrase strand transfer inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
SI conversion factor: To convert creatinine values to μmol/L, multiply by 88.4
a In alphabetic order. The use of abacavir and TAF or TDF is described in the text.
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Theassociationbetweenabacaviruseand increasedriskofmyo-
cardial infarction remains controversial.1,40 Given the uncertainty,
abacavir shouldbeusedwithcautionoravoided inpatientswhohave
or are at high risk for cardiovascular disease.
Recommended Initial ART in the Setting of OIs
andMalignancies
Choice of ART regimen in the setting of OIs and malignancies is
guided by drug-drug interactions with the antimicrobial or chemo-
therapy regimen. Unboosted InSTI-based regimens are recom-
mended. In the setting of malignancy, OI prophylaxis should be in-
stituted, regardless of CD4 cell count, according to specific
chemotherapy regimens used.
The recommended regimens for initial ART in the setting of rifa-
mycin-basedantituberculosistherapyare2NRTIs(excludingTAF)plus
efavirenz (600mgdaily), raltegravir (800mgtwicedaily),ordolute-
gravir (50mg twice daily) (evidence ratingAIa).1,41 Coadministration
of bictegravir (along with TAF/emtricitabine) twice daily with rif-
ampin for 28 days is not recommended, owing to significantly de-
creased area under the curve (AUC) and peak serum concentration
after administration (Cmax) for bictegravir (evidence rating AIIa).
42
When TAF is administered with rifampin, plasma TAF Cmax and AUC
aswell as intracellular tenofovir diphosphate levelswere decreased;
however, intracellular tenofovir diphosphate concentrations were
higher than those achieved with standard-dose TDF. Further evalu-
ation of TAF in tuberculosis co-infection is underway.43 Boosted PIs
should be used only if an efavirenz- or InSTI-based regimen is not an
option, and rifabutin (150 mg daily) should be substituted for rif-
ampin in the antituberculosis regimen (evidence rating AIa).1
For latent tuberculosis, a 1-monthcourseofdaily rifapentineplus
isoniazid was equivalent to 9 months of isoniazid in persons with
HIV.44 Daily rifapentine can be safely administered with efavirenz-
based ART. Once-weekly rifapentine/isoniazid is also safe, well-
tolerated,andhasanacceptablepharmacokineticprofilewhenused
with raltegravir. Dolutegravir-based regimens should not be used
with rifapentine/isoniazid for treatment or prevention of tubercu-
losis, pending further evaluation.45
When and How to Switch
Recommendations for when and how to switch ART regimens are
summarized in Box 3. The most common reasons for switching
therapy are regimen simplification, newly diagnosed comorbidi-
ties (or to prevent comorbid conditions), and management of in-
teractionswithdrugsor supplements. In addition to these reasons,
a regimen switch may be required to minimize the patient’s insur-
ance co-payments or to satisfy payer formulary requirements.
Switching from older antiretroviral regimens should be
considered when there is evidence of or potential for chronic
toxicity, drug-drug interactions, or emergent adverse effects
with current regimens.1,31,46 Proactive switching from TDF- to
TAF-containing regimens to minimize renal or bone adverse ef-
fects may be beneficial.47 Care should be taken when switch-
ing from regimens boosted with ritonavir to ones boosted
with cobicistat because of different drug-drug interactions.48
In patients without a history of treatment failure, data support
switching from regimens containing TDF to single-tablet
regimens including dolutegravir/abacavir/lamivudine,46,49
dolutegravir/rilpivirine,31 elvitegravir/cobicistat/emtricitabine/TAF,1
rilpivirine/emtricitabine/TAF,50 darunavir/cobicistat/emtricitabine
/TAF,51 and bictegravir/emtricitabine/TAF.20 The switch to TAF-
containing regimens is effective in maintaining HIV and HBV sup-
pression in HIV/HBV co-infection.52
Table 3. Initial Non-InSTI Antiretroviral Treatmenta,b,c
Regimen Advantages Disadvantages
Darunavir (boosted with
cobicistat or ritonavir) plus
TAF/emtricitabine or
TDF/emtricitabine
Low risk of resistance with virologic failure, even with intermittent
adherence
Available as a single tablet regimen in Europe and perhaps soon in the
United States (darunavir/cobicistat/TAF/emtricitabine)24
Can be started without results of HLA-B*5701, hepatitis B, and resistance
testing
Requires pharmacokinetic boosting; many drug
interactions
Ritonavir-boosted darunavir inferior to
raltegravir and dolutegravir in comparative
clinical trials, largely because of lower tolerability
Cobicistat should not be given in pregnancy
because of inadequate plasma levels
Efavirenz/TDF/emtricitabine High efficacy in patients with baseline HIV RNA levels >100 000 copies/mL
Extensive experience in patients with concomitant tuberculosis
Widely available globally
Available as a generic coformulation at 600 or 400 mg with TDF/lamivudine
Relatively high rate of rash
No single-tablet form available with TAF
Efavirenz may cause neuropsychiatric adverse
effects
Increased risk of suicidality; avoid in patients with
a history of depression
Rilpivirine/TAF (or
TDF)/emtricitabine
Lowest risk of rash among NNRTI-based therapies
Low risk of metabolic adverse effects
Not recommended for patients with HIV RNA
levels >100 000 copies/mL or CD4 cell count
<200/μL because of increased risk of virologic
failure
Must be taken with a meal (at least 390 calories)
to optimize absorption
Should not be administered with proton-pump
inhibitors; stagger dosing if given with an H2
blocker
Abbreviations: InSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside
reverse transcriptase inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir
disoproxil fumarate.
a In alphabetic order by first component. Initial NNRTI-based regimens should
not be used without baseline resistance data because of the possible presence
of transmitted NNRTI-resistant virus. In the rare circumstance in which
maraviroc might be included in initial therapy, initiation should not occur
before confirmation of CC chemokine receptor 5 tropism.
bOf note, doravirine, an investigational NNRTI, is currently under regulatory
review. If approved, doravirine/lamivudine/TDF would likely be an effective
initial regimen in patients for whom use of an InSTI-containing regimen
is not possible.
c See text with regard to interchanging TDF for TAF and interchanging
emtricitabine for lamivudine and vice versa.
Clinical Review& Education Special Communication Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
384 JAMA July 24/31, 2018 Volume 320, Number 4 (Reprinted) jama.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 09/05/2018
Simplification from a boosted PI53 or from emtricitabine/TAF
plus dolutegravir54 to a single-tablet bictegravir/emtricitabine/TAF
regimen maintained viral suppression above 90%. Switching to 2
antiretroviral drugshasbeenused to reduceNRTI-relatedbone, kid-
ney, and cardiovascular complications and cost. Dolutegravir/
rilpivirinemaintainedvirologic suppression in patientswith nopre-
vious virologic failure or evidence of resistancewho switched from
a 3-drug ART regimen.31 Dual-therapy regimens that include a
boostedPI (lopinavir, atazanavir, ordarunavir) and lamivudinewere
noninferior to3-drug regimens inmaintenanceofvirologic suppres-
sion up to 2 years.55-57 Dolutegravir and lamivudinemaintained vi-
rologic suppression to 48 weeks among patients with no prior
virologic failure or transmitted NRTI resistance.58,59
Feweroptionsexist for regimensimplification invirologicallysup-
pressed individuals in whom several previous regimens have failed
over time. Preexistent NRTI and NNRTI mutations were associated
withviral reboundafter switching to rilpivirine/emtricitabine/TDF.60
Darunavir/cobicistat/emtricitabine/TAFmaintainedvirologicsuppres-
sion in patients switching from a boosted PI plus emtricitabine/TDF,
even if there was previous virologic failure, provided there was
no history of darunavir failure or darunavir-resistance mutations.51
Elvitegravir/cobicistat/emtricitabine/TAF combined with darunavir
taken once daily effectively maintained virologic suppression in
patients with 2-class drug resistance (up to 3 thymidine analogue–
associatedmutationsbutnomulti-NRTIordarunavirmutations)while
takingmultidrug regimens.61
MonotherapywithPIsor InSTIs asamaintenancestrategy isnot
recommended because of higher rates of virologic rebound,1,62-65
often with resistant virus (evidence rating AIIb).62,63
Virologic Failure
Virologic failure is increasingly uncommon with currently recom-
mended ART regimens. Exploration for reasons of inconsistent ad-
herence, drug-drug interactions, and collation of all resistancemu-
tations identified by genotype, along with the ART history, are
required to select a new treatment regimen.
For failure of an initial NNRTI-based regimen, dolutegravir plus
NRTIs was superior to lopinavir plus NRTIs when the next regimen
included at least 1 active NRTI.66 For failure of initial PI-based or
InSTI-basedtherapy(withoutresistance),boostedPI-ordolutegravir-
based therapy with 1 or 2 fully active NRTIs should be effective.
For virologic failure after initial raltegravir- or elvitegravir-based
regimens with the presence of integrase mutations, dolutegravir
(50mgtwicedaily)with at least 1 other activedrugmaybeeffective,
but clinical data are lacking.1 For virologic failurewithmore complex
treatment history, therapy with at least 2 fully active drugs from
Box 3. Selected Recommendations forWhen andHow to Switch ART Regimens
• Review of the ART treatment history, regimen tolerability,
comedications, and results of prior resistance tests is
recommended before any treatment switches are made
(evidence rating AIa).
• In patients with NRTI mutations, switching from a boosted PI
to a regimen containing a drug with a low genetic barrier to
resistance (eg, NNRTI or raltegravir) is not recommended
(evidence rating AIa).
• HIV viral load should be checked 1 month after switching regimens
to ensure virologic suppression has beenmaintained
(evidence rating BIII).
SwitchingWhenVirologically Suppressed
• Patients taking older ART drugs with known toxicity should be
questioned carefully to identify subtle adverse effects of which
theymay be unaware or that theymay not attribute to the drug.
The presence of these toxicities should prompt a change in
regimen (evidence rating BIII).
• In general, if the older regimen is well tolerated without evidence
of toxicity, there is little reason to switch to a newer regimen
(evidence rating BIII).
• Proactive switching from TDF to TAF is recommended for patients
at high risk of renal or bone toxicity (evidence rating BIa). Review
of comedications is essential to ensure no change in dosing is
required with the use of TAF.
• Switching from 3-drug regimens to certain 2-drug regimens in the
setting of viral suppression, using dolutegravir/rilpivirine (evidence
rating AIa), a boosted PI with lamivudine (evidence rating AIIa),
or dolutegravir with lamivudine (evidence rating AIIa) can be used
in patients with no prior virologic failure or transmitted drug
resistance. (Longer-term follow-up is needed to confirm the
durability of these strategies).
• Patients who are co-infected with HIV and HBV should receive a
regimen that contains 2 drugs active against HBV, usually TAF or
TDF plus lamivudine or emtricitabine, in addition to a third ART
drug (evidence rating AIIa). Such patients should generally not be
switched to 2-drug ART.
• Monotherapy with boosted PIs or dolutegravir is not
recommended (evidence rating AIIa).
Switching for Virologic Failure
• Resistance testing is recommended while taking the failing
ART regimen or within 4 weeks of stopping
(evidence rating AIIa).
• Virologic failure should be confirmed and, if resistance
is identified, a prompt switch to another active regimen
using results of current and past resistance testing to prevent
accumulation of additional resistancemutations is recommended
(evidence rating BIIa).
• Dolutegravir, plus 2 NRTIs (with at least 1 active by genotype)
is recommended after initial treatment failure with an NNRTI
(evidence rating AIa).
• A boosted PI plus 2 NRTIs (with at least 1 active NRTI) are
recommended for initial treatment failure of an InSTI-containing
regimen (evidence rating AIII).
• Dolutegravir plus at least 1 fully active other agent may be
effective in the setting of raltegravir or elvitegravir resistance.
Dolutegravir should be dosed twice daily in this setting
(evidence rating BIII).
• A single active agent added to a failing regimen is not
recommended (evidence rating AIa).
• For multiclass resistance, the next regimen should be constructed
using drugs from new classes if available (evidence rating BIII).
Abbreviations: ART, antiretroviral therapy; HBV, hepatitis B virus;
NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide;
TDF, tenofovir disoproxil fumarate.
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differentantiretroviralclasses,perhaps includingmaraviroc intheset-
tingofCCchemokinereceptor5(CCR5)–tropicvirus, isrecommended.
Ibalizumab, ananti-CD4monoclonal antibody that inhibitsHIV
cell entry viaCD4binding, is active againstCCR5- andC-X-C chemo-
kine receptor 4 (CXCR4)–tropic HIV isolates andmay be useful as a
fully active agent for patients with multiclass-resistant virus (evi-
dence rating BII). Almost 50% of adults with virologic failure from
multidrug-resistantHIVachievedundetectableHIVRNA levels at24
weeks after receipt of biweekly intravenous ibalizumab (800mg)
with at least 1 other active drug.67,68
Laboratory Monitoring
Recommendations for laboratory monitoring are summarized in
Table 4 and Box 4. All individuals who have ever been sexually ac-
tive should be tested for HIV at least once in their lives (evidence
rating AIII). Risk for HIV often changes over a person’s lifetime; risk
evaluation is recommended at each routine clinical visit (evidence
rating AIII). For men who have sex with men (MSM), transgender
women,peoplewho injectdrugs,andotherswith increasedrisk, test-
ing is recommended at least annually and perhaps as frequently as
every3months (evidence ratingBIII).69Diagnosis of sexually trans-
mitted infections (STIs) and HCV can help identify individuals who
shouldbe testedmore regularly forHIVandwhomightbenefit from
preexposure prophylaxis (PrEP) (evidence rating BIII).70-72 Testing
performedwithassays thatmeasureHIVantibodyandantigen is rec-
ommended because it can take 3 weeks or longer for HIV antibod-
ies tobedetectedafter initial infection. In contrast,HIVRNAorcom-
binationantibodywithp24antigen tests that candetectHIVwithin
10 to 14 days after infection are recommended (evidence rating
AIIa).73Relyingonsymptomsof theacuteretroviral syndrometotrig-
ger testing will miss infections because acute infection may be
asymptomatic.1,74,75 Available home-basedHIV tests do not detect
acute HIV infection but can be useful for people without access to
testing otherwise.76 All available tests can have false-positive re-
sults, so confirmatory measurement of HIV RNA level is recom-
mended before ART initiation, although treatment can be initiated
before results are available (evidence rating AIa).
Before starting ART, recommended laboratory monitoring in-
cludesHIVRNA level, CD4cell count, and reverse transcriptase and
protease genotype (InSTI genotyping generally is not recom-
mended because it is not cost-effective)77; general health (testing
for kidney/liver function, lipid levels, completebloodcell count, glu-
cose level, andpregnancy status); and co-infections (hepatitis A, B,
and C, tuberculosis, and STIs) (evidence rating AIa). Unless preex-
isting kidney or liver damage or high likelihood of transmitted drug
resistance exists, the results of these tests should not delay start of
ART (evidence rating BIII).78-81 Testing for CCR5 tropism is recom-
mended each time when considering maraviroc, and HLA-B*5701
testing (only needed once) is recommended before starting aba-
cavir (evidence rating AIa).
Monitoring During ART
Within6weeksof startingART,adherenceandtolerabilityof therapy
should be assessed, along with HIV RNA level. HIV RNA suppres-
sionmaytakeupto24weeks,or fasterwith InSTI-basedregimens.1,82
Once the HIV RNA level is below 50 copies/mL, monitoring is rec-
ommended every 3months until suppressed for at least 1 year. Af-
ter that year, monitoring can be performed every 6 months if the
patient maintains consistent medication adherence (evidence rat-
ing AIII). Of note, when monitoring intervals are extended and
therapy fails, resistance has more time to emerge.80
Once viral suppression occurs with ART, CD4 cell counts usu-
ally increase.1,83 CD4 measurements are recommended every 6
months until above 250/μL for at least 1 year with concomitant vi-
ral suppression (evidence ratingBIII).1,84Afterward,CD4cell counts
need not be measured unless ART fails (defined below) or the pa-
tienthasan immunosuppressiveconditionor treatment, suchasste-
roid treatments or chemotherapy (evidence rating AIII).85 Patients
taking ART should have regular clinical and laboratory evaluations,
including age- and risk-appropriate screening.
HIVRNAtesting isused todetect ifART is failing.WhenHIVRNA
level is above 50 copies/mL, repeating measurement of HIV RNA
Table 4. Recommended Laboratory Assessments andMonitoring Across the HIV Care Continuum
Test At HIV Diagnosis During ART At Virologic Failure
HIV RNA level  Within the first 6 weeks of starting ART or a new
ART regimen, then every 3 mo until <50
copies/mL for 1 y, then every 6 mo

CD4 cell count  Every 6 mo until >250/μL for 1 y then stop as
long as virus is suppressed

HIV RT-pro
genotype
 
HIV integrase
genotype
If failing ART regimen
included an InSTI
Viral tropism Each time before the
start of ART that includes
maraviroc
HLA-B*5701  (before
initiating
abacavir; just
once)
 (if considering abacavir and not determined
previously)
Safety testing   
Co-infection (STIs,
tuberculosis,
hepatitis, Pap test)
 
Health maintenance  
Abbreviations: ART, antiretroviral
therapy; InSTI, integrase strand
transfer inhibitor; Pap, Papanicolaou;
RT-pro, reverse transcriptase and
protease; STI, sexually transmitted
infection.
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levelwithin4weeks and reassessing formedication adherenceand
tolerability is recommended (evidence rating AIIb). Virologic fail-
ure is defined as HIV RNA level above 200 copies/mL on at least 2
consecutivemeasurements. Once virologic failure is diagnosed, an
HIVgenotype shouldbeobtainedwhile thepatient is taking the fail-
ing regimen.1 If HIV genotyping is unsuccessful (eg, HIV RNA level
is <1000 copies/mL), a proviral DNA analysis using deep sequenc-
ing methods may be used.86 For virologic failure of InSTI-
containing ART, integrase resistance testing is recommended (evi-
denceratingAIII).1,87-89Onceanewregimen isstarted,HIVRNAlevel
should be checked4 to6weeks after initiation, following the same
schedule as for monitoring of initial therapy (evidence rating AIII).1
Optimal care for patients with persistent viremia between 50
and 200 copies/mL is unclear. The ART regimen should be contin-
ued,withassessmentofmedicationadherence(evidenceratingBIII).
There is no indication to intensify the regimen with additional
antiretrovirals.90
Engagement in Care and ART Adherence
Recommendations for engagement in care andART adherence are
summarized in Box 5. The HIV care continuum provides a frame-
work toenhance individual healthoutcomesandmaximize theben-
efits afforded by treatment as prevention. In the setting of sus-
tained viral suppression, individuals with HIV do not transmit HIV
to sexual partners (describedas “undetectable = untransmissable”
[U = U]).91,92 In the United States, 22% of initial HIV diagnoses oc-
cur within 3 months of an AIDS diagnosis, indicating that persons
are entering HIV care late.93 Clinicians not offering HIV testing in
emergency departments and acute medical care settings appears
to be amajor limitation in early diagnosis of HIV.94
Monitoring successive steps on the HIV care continuum helps
address barriers that impede initial linkage, subsequent retention,
andsuccessful reengagementofpatients lost to care.1Missedmedi-
cal care visits can be assessed in real time and are consistently as-
sociatedwith poorHIV outcomes.95 Assessment ofmissed visits in
the prior year predicts future risk formissing future appointments,
allowing for clinic-level intervention.96 Coordination of appoint-
mentdatawithpublichealthsurveillancesystems(eg, “DatatoCare”)
enhances linkage to, and retention and reengagement in, care.97,98
Resource-intensive interventions among vulnerable individu-
als (eg, those hospitalized or with substance use disorders) have
yieldedmodest short-term improvements in care engagement and
viral suppression.99,100Cash incentives toencourageadherencewith
treatment and follow-updonotwork consistently andgenerally are
not recommended (evidence ratingAIa).99,101However, noncash in-
centivesaspartof combinationstrategiesareeffective.102,103Tiered
strategiesusing risk stratification to identifyhigh-acuitypatients are
recommended (evidence ratingCIIb), as is providing low-threshold
medical care, such as open access (ie, “walk in”) clinics, integrated
withhigh-intensityoutreach implemented inconjunctionwithpublic
Box 4. Selected Recommendations for LaboratoryMonitoring
All persons who have ever been sexually active should be tested for
HIV at least once in their lives (evidence rating AIII).
Risk for HIV often changes over a person’s lifetime; risk evaluation is
recommended at each routine clinical visit (evidence rating AIII).
For sexually active menwho have sex with men and for transgender
women, people who inject drugs, and others at increased risk,
testing is recommended at least annually and as frequently as every
3months (evidence rating BIII).
Diagnosis of sexually transmitted infections and hepatitis C virus can
help identify persons who should be testedmore regularly for HIV
and whomight benefit from preexposure prophylaxis
(evidence rating BIII).
HIV screening with assays that can detect recent HIV infection,
either an instrument-based combination antigen/antibody assay or
a combination of a stand-alone antibody assay and nucleic acid
testing, is recommended (evidence rating AIIa).
Persons with ongoing condomless sexual exposures or sharing of
needles or works need to be tested with assays that can detect HIV
RNA or with combination antibody + p24 antigen tests
(evidence rating AIIa). Individuals with signs or symptoms of acute
or primary HIV infection should be tested with HIV RNA assays.
All available tests can have false-positive results, so additional
testing with an HIV viral load is recommended before ART initiation,
although treatment may be started before results are available
(evidence rating AIa).
HIV genotype to assess transmitted NRTI and NNRTI resistance
should be performed; InSTI genotyping at baseline is not
recommended unless exposure to a partner with InSTI resistance
is suspected (evidence rating BIII).
CCR5 tropism testing is recommended each time when considering
maraviroc and HLA-B*5701 testing (only needed once) before use
of abacavir (evidence rating AIa).
Once HIV RNA level is below 50 copies/mL, monitoring is
recommended every 3months until virus is suppressed for at least
a year. After 1 year of viral suppression, monitoring can be reduced
to every 6months if the patient maintains consistent medication
adherence (evidence rating AIII).
Measurement of CD4 cell counts is recommended every 6months
until cell counts are above 250/μL for at least 1 year with
concomitant viral suppression (evidence rating BIII).
Age- and risk-appropriate screening for STIs at various anatomical
sites, anal or cervical dysplasia, tuberculosis, general health,
andmedication toxicity is recommended
(evidence rating AIII).
Once a viral load above 50 copies/mL is detected, measurement
should be repeated within 4 weeks, and reassessing for
medication adherence and tolerability is recommended
(evidence rating AIII).
Measurement of viral load at 4 to 6 weeks after starting a new ART
regimen is recommended (evidence rating AIII).
If the viral load has not declined, adherence and toxicity should
be discussed with the patient. If adherence appears to be
sufficient, a genotype assay is recommended
(evidence rating AIII).
Abbreviations: ART, antiretroviral therapy; CCR5, CC chemokine receptor 5;
InSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor;
STI, sexually transmitted infection.
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health agencies, jails, housing, and mental health case manage-
ment (evidence rating CIII).104
Guidelines exist for ART adherence monitoring and
interventions.105 Systematic screening for ART medication adher-
enceviapatientself-reportusingvalidated instrumentsorusingphar-
macy refill measures, and not relying solely on plasma viral load, is
recommended.1 Individuals with suboptimal adherence should be
assessed for inadequate housing,106-108 food insecurity,109-111 ac-
tive substanceuse,110 psychiatric disorders,medication adverse ef-
fects, and pill burden.
Internalized stigma, defined as a patient’s negative feelings or
thoughts related to their HIV status, and depression are associated
with poor medication adherence, visit retention, and clinical
outcomes.112-114Chronicdepression increasestherisk formissedclinic
visits, virologic failure, anda2-fold increase inmortality risk.115Treat-
mentwith antidepressants can improvevirologic suppression, CD4
cell counts, and remission from clinical symptoms.116
Cost
From the patient perspective, themost relevant cost is the out-of-
pocket expenseof accessing treatment. Thepayerperspective is to
use the lowest-cost medications to avoid the most expensive and
severe HIV outcomes (eg, hospitalizations). The latter perspective
oftenplacesgreatervalueon immediatecostlyoutcomesrather than
prevention of events occurring remotely in time (eg, renal or car-
diovascular toxicity). Forexample, apatientandclinicianmightvalue
therenalandbonesafetyofTAFover thatofTDF,but thepayermight
determine that the similar virologic efficacy does not justify the
higher cost of TAF.117
The societal perspective considers the cost and outcomes for
all parties involved. Since this perspectivedoesnot favoronegroup
over another, it is adopted bymost cost-effectiveness analyses for
which therapies are considered in relation to each other, with the
one providing the greatest return on investment being preferred.
For example, despite its high cost, the benefits of ART are so large
it is considered cost-effective.118-120
The availability of more generic antiretrovirals and the use of
2-drug regimens could reduce the costs of treatment substantially.
Generic antiretrovirals have already reduced the cost of HIV treat-
mentglobally, allowingmillionsofpatients tobe treated in resource-
limited settings. Indevelopedcountries,manyantiretroviral agents
and coformulations are available as lower-cost generics. Limita-
tions include a forced switch frombranded coformulated regimens
toseparatepills121,122;morepharmacyco-pays for separateprescrip-
tions; use of older agents that are not part of current recom-
mended regimens; and high costs if an insufficient number of ge-
neric manufacturers enter themarket. However, a modeling study
found that useof a partially generic regimen includingmultiple pills
would be highly cost-effective.123
Ultimately, the first priority for clinicians and patients is to find
themosteffectiveandsafest treatment. Ifmultipleoptionsexistwith
similar outcomes, choosing the lowest-cost options makes intui-
tive sense, provided there are no additional patient cost barriers.
Prevention
Recommendations for the prevention of HIV infection are summa-
rized inBox6. Use of antiretrovirals for HIV prevention spans 3 do-
mains: treatment as prevention, prophylaxis for currently unin-
fected individuals (PrEP andpostexposure prophylaxis [PEP]), and
prevention of mother-to-child transmission.
Asnoted,maintainingU = Ustatus requires continuedviral sup-
pression. There are 2 caveats to consider when counseling patients
aboutU = U:Theonlytransmissionsthatoccurredinstudieshappened
early after starting treatment and 3 to 6months of viral suppression
maythereforeberequired;anddurableviralsuppressioncannotbeas-
sessedbasedonasinglemeasurement.124 Importantly, transmission
Box 5. Selected Recommendations for Engagement
in Care and ART Adherence
Routine, opt-out HIV screening is recommended in primary
medical care settings, emergency departments, and for all
pregnant women (evidence rating AIIa).
Routine screening and treatment for depression is recommended
(evidence rating AIIa).
Systematic monitoring of time to care linkage after initial HIV
diagnosis, retention in care, reengagement in care, ART
adherence, and rates of viral suppression is recommended in all
care settings and at a population level (evidence rating AIIa).
Brief, strengths-based case management is recommended after
HIV diagnosis to facilitate linkage to care (evidence rating AIa).
Systematic monitoring of missed clinic visits and rapid intervention
after a missed visit is recommended (evidence rating AIIa).
Personal telephone and interactive text reminders in advance of
scheduled appointments and shortly after missed appointments
(eg, 24-48 hours) are recommended (evidence rating AIa).
Adherencemonitoring using patients’ self-report obtained by
validated adherence instruments and pharmacy refill data is
recommended (evidence rating AIIa).
Integration of directly observedART inmethadonemaintenance
programs (evidence rating BIa) and as a treatment strategy among
personswith substance use disorders (evidence rating BIa) and those
who are incarcerated or released to the community (evidence rating
CIII) is recommended to enhance adherence and viral suppression.
Opioid substitution therapy for opioid-dependent patients is
recommended (evidence rating AIa).
Rapid HIV test algorithmsmay be used to confirm a preliminary
positive rapid test result, allowing for same-day referral to
treatment from nonclinical settings (evidence rating AIa).
Use of public health surveillance in conjunction with clinic-level
data to guide individual-level linkage and reengagement in care
activities is recommended (evidence rating BIIa).
Cash financial incentives for clinic appointment attendance and
achievement of viral suppression are generally not recommended
as a retention-in-care strategy (evidence rating AIa).
Data-driven risk stratification to identify high-acuity, high-need
patients for combination intervention strategies to improve
care engagement and viral suppression is recommended
(evidence rating CIIb).
Screening for and addressing housing instability, food insecurity,
ongoing substance use, psychiatric disorders, medication adverse
effects, and pill burden is recommended (evidence rating BIIa).
Abbreviation: ART, antiretroviral therapy.
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canoccurwhenanHIV-seronegativepartner inaserodiscordant rela-
tionship has partners outside of that relationship.
Guidelines exist for occupational (needle stick and fluid splash
tomucousmembranes)125 andnonoccupational (sexual- and injec-
tion–drug related) PEP.126 PEP should be started as soon as pos-
sible after a potential exposure to maximize effectiveness.125
Abacavir-based PEP is not recommended unless the exposed pa-
tient isknowntobeHLA-B*5701negative(evidenceratingAIII).Avail-
abledataare insufficient torecommendTAF-basedregimensforPEP.
PrEPwithTDF/emtricitabine ishighlyeffective inpreventingHIV
acquisition from sexual exposures.1 TDF alone prevented infection
in people who inject drugs, but TDF/emtricitabine is recom-
mendedfor thesepersons.Substanceuseandmedicalhistories (par-
ticularly renal andbonedisease) are important in decidingwhether
to provide PrEP to best balance potential risks and benefits. PrEP
is recommended for populations with an HIV incidence above 2%
per year (evidence rating AIII) and for HIV-seronegative partners
of HIV-infected persons who are not consistently virally sup-
pressed.127,128 Unlike condoms, PrEP does not prevent other STIs.
For peoplewho inject drugs, clean injection equipment and access
to substance use treatment should be available.
Daily TDF/emtricitabine is recommended for persons at risk of
HIV through sexual exposure (evidence rating AIa) and for people
who inject drugs (evidence rating BIa).1 Daily dosing is required for
optimalprotection.129This is especially important forwomen,given
that tenofovir concentrates at 10-fold lower levels in vaginal tissue
than in rectal tissue and clearance is faster.130
On-Demand or Event-Driven PrEP (“2-1-1”)
Pericoital TDF/emtricitabine, known as on-demand or event-
driven PrEP, is effective for HIV prevention amongMSM and an al-
ternative to daily PrEP for MSM with infrequent sexual exposures
(evidence rating AIa). The IPERGAY (Intervention Préventive de
l’Exposition aux Risques avec et pour les Gays) study assessed
Box 6. Selected Recommendations for Prevention of HIV Infection
HIV-seropositive and -negative individuals should be reminded that
condoms are required to prevent acquisition of non-HIV STIs
(evidence rating AIIa).
Quarterly screening for asymptomatic STIs is recommended for all
populations with high rates of bacterial STIs and incomplete condom
use (evidence rating AIIa).
Abacavir-based PEP is not recommended unless the exposed patient is
known to be negative for theHLA-B*5701 allele (evidence rating AIII).
PrEP is recommended for populations whose annual HIV incidence is
at least 2% (evidence rating AIII).
Daily TDF/emtricitabine is the recommended regimen for men and
women (evidence rating AIa) and transgender individuals (evidence
rating AIIa) at risk of sexual exposure (evidence rating AIa) and
people who inject drugs (evidence rating BIa).
A 1-week lead-in time is recommended with daily dosing for rectal,
penile, and vaginal exposures with daily TDF/emtricitabine to ensure
adequate tissue levels are achieved (evidence rating CIII).
At PrEP discontinuation, TDF/emtricitabine should continue for 1
week after the last sexual exposure (evidence rating CIII).
For individuals with active HBV infection (detectable HBsAg),
discontinuation of TDF/emtricitabine PrEP could lead to acute HBV
flares or hepatic decompensation, particularly for patients with
hepatic cirrhosis; careful monitoring of HBV infection and liver
function is recommended after discontinuation of TDF/emtricitabine
(evidence rating AIIa).
Pericoital TDF/emtricitabine PrEP, also known as on-demand,
event-driven, or “2-1-1” dosing may be considered as an alternative to
daily PrEP for MSMwith infrequent sexual exposures (evidence
rating AIa). This regimen is not recommended in other risk groups or
in patients with active HBV infection because of the risk of hepatitis
flare and hepatic decompensation (evidence rating BIIa).
If intercourse is planned in the context of 2-1-1 PrEP regimen, the first
(double) dose of TDF/emtricitabine should be taken closer to the
24-hour precoital time than the 2-hour time (evidence rating CIII).
TDF/lamivudine, TAF/emtricitabine, and TDF alone are not
recommended for PrEP (evidence rating BIII).
TDF-based PrEP is not recommended in persons with creatinine
clearance below 60mL/min/1.73 m2 (evidence rating AIIa)
HIV testing, preferably with a combination antigen-antibody assay
(evidence rating AIII), to confirm HIV-seronegative status is
mandatory at time of initiation of TDF/emtricitabine PrEP; HIV RNA
testing should be obtained if acute HIV is suspected.
Measurement of serum creatinine level, determination of estimated
glomerular filtration rate, and HBsAg testing are recommended
before initiation of PrEP but need not impede PrEP initiation
(evidence rating BIII).
During PrEP, intervals of follow-up every 3months are
recommended to allow for HIV testing (evidence rating AIII) and
STI screening (evidence rating AIIa).
HCV serologic testing should be performed at least annually andmore
frequently in the case of elevated transaminase levels or in high-risk
individuals (eg, peoplewho inject drugs) (evidence rating BIIa).
PrEP prescription should not exceed 90 days without interval
testing for HIV infection (evidence rating AIII); a visit 30 days after
PrEP start is recommended for follow-up HIV testing, to assess
adverse effects and support adherence (evidence rating BIII).
Measurement of creatinine level should be performed at least every
6months (evidence rating AIII) andmore frequently for some
patients (eg, those >50 years, taking hypertension or diabetes
medications, or with glomerular filtration rates <90mL/min)
(evidence rating BIIa).
Each PrEP visit should be used to assess and troubleshoot barriers
to adherence to PrEP (evidence rating BIII).
For confirmedHIV infection in the setting of PrEP use, a recommended
initial antiretroviral regimen should be started, pending results of
resistance testing (evidence rating AIII).
For individuals being treated with a course of 3-drug PEP for a recent
exposure who are likely to be at risk of ongoing exposure, a seamless
transition from PEP to PrEP is recommended (evidence rating CIII).
If during PrEP treatment, exposure to HIV is known to occur,
intensification of treatment with additional agent(s) is not
recommended (evidence rating BIII).
Abbreviations: HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus;
HCV, hepatitis C virus; MSM, menwho have sex with men; PEP, postexposure
prophylaxis; PrEP, preexposure prophylaxis; STI, sexually transmitted infection;
TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
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on-demandPrEPwithTDF/emtricitabinegivenas2doseswith food
2to24hoursbeforesex, 1dose24hoursafter the first (double)dose,
and1dose24hours later (“2-1-1”dosing). Forconsecutivesexual con-
tacts,menwere instructed to take 1pill perdayuntil 2days after the
last sexual encounter. With each new sexual encounter, PrEP was
tobe initiatedwith adouble dose, unless the last PrEPdosehadoc-
curredwithin7days, inwhichcaseonly 1preexposuredosewas rec-
ommended.The IPERGAYandPROUD(Pre-exposureOption forRe-
ducingHIV in theUK: ImmediateorDeferred) trials (usingdailyTDF/
emtricitabine) reduced riskby86%.131,132AnanalysisofMSMhaving
infrequent sexual intercourse in the IPERGAY study and subse-
quentopen-label extension studies foundhigh levels of efficacy, in-
cluding in a subgroup who took an average of 2 or 3 doses of TDF/
emtricitabine per week.133,134 Clinical experience with on-demand
PrEP confirmed efficacy of this dosing amongMSM.135,136 The 2-1-1
regimenachievedtargetexposuresof tenofovirdiphosphateandem-
tricitabine triphosphate in colorectal tissue at the time of coitus in
81%and98%of thepopulationwhenadministered2 and24hours
before coitus, respectively; target exposure was sustained for the
next 10days.130,137-139 If intercourse isplanned, thefirst (double)dose
of TDF/emtricitabine should be taken closer to the 24-hour preco-
ital time than the 2-hour time (evidence rating CIII).
Lack of data among heterosexual men and women, transgen-
der men and women, and people who inject drugs precludes rec-
ommendation of the 2-1-1 regimen in these populations (evidence
rating AIII). The 2-1-1 regimen also is not recommended for patients
with active HBV, because of risks of HBV reactivation and HBV re-
sistance (evidence rating BIIa).
Regimen Choice and LaboratoryMonitoring
TDF/emtricitabine is the recommended PrEP agent (evidence rat-
ing BIII); TDF/lamivudine, TAF/emtricitabine, or TDF alone are not
recommended for PrEP at this time (evidence rating BIII). TDF-
based PrEP is not recommended for persons with creatinine clear-
ance below 60mL/min/1.73 m2 (evidence rating AIIa). Glomerular
dysfunctionmayoccurwith therapy,particularly in individualsolder
than 50 years. The dysfunction is usually reversible, and rechal-
lengewithPrEP isoftenpossible.140Suchpatients shouldhavemore
frequent creatinine clearancemonitoring (evidence rating BIIa).
A combination HIV antigen-antibody assay should be per-
formedwithin 7days before initiation of TDF/emtricitabinePrEP to
excludeHIV infection (evidence rating AIII). AnHIVRNA assaymay
be needed to exclude acute HIV infection in high-risk populations.
A 1-month follow-upvisit is recommended toassess adherenceand
tolerability and toensure theabsenceofprimaryHIV infection (evi-
dence rating BIII).141 Subsequent follow-up is recommended every
3months to allow for STI screening (urine, throat, anal, and vaginal
tests) (evidence rating AIIa) and HIV testing (evidence rating AIII).
HCVserologic testingshouldbeperformedat leastannuallyandmore
frequently in high-risk individuals (eg, people who inject drugs) or
thosewithelevated transaminase levels (evidence ratingBIIa). PrEP
prescription shouldnot exceed90dayswithout interval testing for
HIV infection (evidence rating AIII).
Seroconversion in the Setting of PrEP
DiagnosingHIV infection in individuals takingPrEPcanbechalleng-
ing because PrEP can alter and delay antibody responses and de-
creaseplasmaHIVRNA levels.142,143AnypositiveHIV screening test
result in this setting should prompt immediate confirmatory test-
ingwithHIVRNAandgenotype testing if confirmed. For suspected
HIV infection or equivocal screening test results, PrEP should be
stopped and other prevention methods used until HIV infection is
confirmedorexcluded. IfHIV infection is confirmedor strongly sus-
pected, fully suppressive ART should be administered as quickly as
possiblewitha recommendedregimen; resistance testingshouldbe
performedand treatment altered, as needed (evidence ratingAIII).
Resistance (typically with an M184V/I mutation) has been ob-
served rarely, usually when PrEP with TDF/emtricitabine is initi-
ated during undiagnosed acute HIV infection.
Additional Considerations
For high-risk individuals (including those who do not use safer sex
or injection practices), the office visit to discuss PrEP is an oppor-
tunity to reduce risk. Same-dayPrEP initiation is reasonable in some
clinical scenarios. Asymptomatic individuals who are HIV-
seronegative by rapid assay could initiate daily oral TDF/
emtricitabinewithout awaiting results of the concomitant baseline
testingof creatinine level, hepatitisB surfaceantigen level, STIs, and
HIV by fourth-generation assay. Condom use should be encour-
agedforallgenitalcontact topreventSTIs (evidenceratingAIIa).TDF/
emtricitabine PrEP is not fail-safe, and seroconversion despite ex-
cellent adherence has been reported in cases of high inoculum or
viral resistance.142,144,145
Unanticipated interruptions inPrEPdelivery (eg, insurance cov-
erage lapse, incarceration,andrelocation)havebeenassociatedwith
seroconversions and should be avoided.146 For individuals being
treated with a course of 3-drug PEP for a recent exposure, who are
likely tobeat riskofongoingexposure,aseamlesstransitionfromPEP
to PrEP is recommended (evidence rating CIII). Given a negative re-
sult for a fourth-generation instrumented test (eg, combinationHIV
antigen-antibodytest)at theconclusionofa28-dayPEPcourse,PrEP
with daily TDF/emtricitabinemay be initiated or resumed.147
Future Directions
New treatments continue to be developed, most notably long-
acting formulations of antiretrovirals for treatment and preven-
tion. Injectable rilpivirine combinedwith cabotegravirwas success-
ful inphase2studies148and isbeingevaluated inphase3clinical trials
(NCT03299049). Also in development are implantable sustained-
release platforms, nanoparticles, viral vector delivery, monoclonal
antibodies, and other long-acting oral agents.1
Injectable and other long-acting preparations for PrEP, such as
injectable cabotegravir149and thedapivirinevaginal ring, are inclini-
cal trials (NCT01617096).Open-label trials of thedapivirine vaginal
ringdemonstratedhigheruptakeandadherence than in theblinded
trials, aswell asHIV-1 incidence thatwashalf theexpected rate.150,151
Broadlyneutralizingantibodies (bNAbs) targetingconservedan-
tigenic sites on the HIV-1 envelope trimer are being evaluated for
therapyandprevention.152-154Newerapproaches to increase thepo-
tency, breadth,155 and half-life156,157 of bNAbs, evaluate different
methodsofbNAbadministration,158 andassess theefficacyof com-
binations of bNAbs are being investigated.159,160
HIV cure efforts focus on inducing HIV expression from latently
infectedcells, augmenting the immunesystemtoclear infectedcells
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(eg, with therapeutic vaccines, checkpoint inhibitors, chimeric anti-
genreceptorTcells), andusinggenetherapytomodifyhostCD4cells
to make them resistant to HIV. Using ART with a toll-like receptor 7
agonist (an innate immune stimulant) plus a bNAb during acute in-
fection inmonkeys suppressedviral reboundafter stoppingART in a
substantialnumberofanimals.161These interventionsaremovingfor-
ward in clinical trials.
Clinicians who care for patients with HIV have a major role in
advocating for programs and their patients at the local, national,
and international levels. Advocacy should go beyond access to
ART and include access to mental health and substance abuse
services as well as efforts to end policies such as HIV criminaliza-
tion that impede the ability to provide evidence-based care and
prevention services.
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